Literature DB >> 19369524

Comparison of different methods of determining beta-lactam susceptibility in clinical strains of Pseudomonas aeruginosa.

Eva Torres1, Rosa Villanueva1, Germán Bou1.   

Abstract

One hundred and one randomly selected (2003-2005) clinical isolates of Pseudomonas aeruginosa were used to assess the quantitative (MIC) and qualitative (susceptibility category) agreement between the microdilution broth reference method (RM) and disc diffusion (DD), Etest and the VITEK 2 automated susceptibility test system for determination of the susceptibility of P. aeruginosa to piperacillin (PIP), PIP-tazobactam (TZP), ceftazidime (CAZ), aztreonam (ATM) cefepime (FEP) and imipenem (IMP). The results obtained by the RM were compared with those obtained by the other methods. The RM and DD were performed according to CLSI criteria. Etest and VITEK 2 were according to the manufacturer's instructions. The Advanced Expert System (AES), which interprets MICs generated by VITEK 2, was modified with new rules of interpretation. Overall, VITEK 2 showed the lowest MIC90 values for the six antibiotics. The RM categorical testing (susceptibility and resistance) rates with P. aeruginosa were 11.8 and 88.1 for PIP, 22.7 and 77.2 for TZP, 14.8 and 78.2 for CAZ, 12.8 and 54.4 for ATM, 16.8 and 75.3 for FEP, and 7.9 and 90.1 for IMP, respectively. Very major errors (false susceptible) were only detected for ATM and FEP with DD and for IMP with three methods. Major errors (false resistant) were generally acceptable for all antibiotics except TZP. VITEK 2 yielded a high level of minor errors (trends toward false susceptibility), mainly with CAZ and FEP. A good agreement was obtained for all antibiotics/methods assayed, thus highlighting the importance of the AES for categorization of beta-lactam susceptibility in P. aeruginosa.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19369524     DOI: 10.1099/jmm.0.005587-0

Source DB:  PubMed          Journal:  J Med Microbiol        ISSN: 0022-2615            Impact factor:   2.472


  5 in total

Review 1.  Expert systems in clinical microbiology.

Authors:  Trevor Winstanley; Patrice Courvalin
Journal:  Clin Microbiol Rev       Date:  2011-07       Impact factor: 26.132

Review 2.  Are we ready for novel detection methods to treat respiratory pathogens in hospital-acquired pneumonia?

Authors:  Andrea Endimiani; Kristine M Hujer; Andrea M Hujer; Sebastian Kurz; Michael R Jacobs; David S Perlin; Robert A Bonomo
Journal:  Clin Infect Dis       Date:  2011-05       Impact factor: 9.079

3.  Direct disk diffusion test using European Clinical Antimicrobial Susceptibility Testing breakpoints provides reliable results compared with the standard method.

Authors:  Sofia Stokkou; Gernot Geginat; Dirk Schlüter; Ina Tammer
Journal:  Eur J Microbiol Immunol (Bp)       Date:  2015-03-26

4.  Performance of Vitek 2 for Antimicrobial Susceptibility Testing of Acinetobacter baumannii, Pseudomonas aeruginosa, and Stenotrophomonas maltophilia with Vitek 2 (2009 FDA) and CLSI M100S 26th Edition Breakpoints.

Authors:  April M Bobenchik; Eszter Deak; Janet A Hindler; Carmen L Charlton; Romney M Humphries
Journal:  J Clin Microbiol       Date:  2016-11-23       Impact factor: 5.948

5.  Pseudomonas Endocarditis with an unstable phenotype: the challenges of isolate characterization and Carbapenem stewardship with a partial review of the literature.

Authors:  Emil Lesho; Erik Snesrud; Yoon Kwak; Ana Ong; Rosslyn Maybank; Maryrose Laguio-Vila; Ann R Falsey; Mary Hinkle
Journal:  Antimicrob Resist Infect Control       Date:  2017-08-29       Impact factor: 4.887

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.